Effects of valsartan versus olmesartan addition to amlodipine/ hydrochlorothiazide combination in treating stage 2 hypertensive patients

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 5, 2012, Pages 629-636

  Fogari, Roberto ^a   Zoppi, Annalisa ^a   Mugellini, Amedeo ^a   Preti, Paola ^a   Perrone, Tiziano ^a   Maffioli, Pamela ^a   Derosa, Giuseppe ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Amlodipine; Combination therapy; Hydroclorotiazide; Hypertension; Valsartan

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; HYDROCHLOROTHIAZIDE; OLMESARTAN; PLACEBO; VALSARTAN;

ADULT; AGED; AMBULATORY CARE; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE;

ADULT; AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DRUG COMBINATIONS; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; TETRAZOLES; VALINE;

EID: 84858631158     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.667077     Document Type: Article

References (27)

1. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003;289(19):2560-72
2. Mancia G, De Backer G, Dominiczak A, et al. The task force for the management of arterial hypertension of the European Society of Hypertension, the task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28(12):1462-536
3. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: The cycle repeats. Drugs 2002;62(3):443-62 (Pubitemid 34208333)
4. Neutel JM. The role of combination therapy in the management of hypertension. Nephrol Dial Transplant 2006;21:1469-73 (Pubitemid 43834634)
5. Zappe DH, Sowers JR, Hsueh WA, et al. Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome. J Clin Hypertens (Greenwich) 2008;10(12):894-903
6. Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007;21(3):220-4
7. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988 - 2008. JAMA 2010;303(20):2043-50
8. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288:2981-97
9. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 2003;290(21):2805-16 (Pubitemid 37509488)
10. Devereux RB, de Faire U, Fyhrquist F, et al. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. Curr Med Res Opin 2007;23(2):259-70 (Pubitemid 46333373)
11. Jamerson K, Bakris GL, Dahlof B, et al. ACCOMPLISH Investigators. Exceptional early blood pressure control rates: The ACCOMPLISH trial. Blood Press 2007;16(2):80-6 (Pubitemid 47050368)
12. Mancia G, Laurent S, Agabiti-Rosei E, et al. European Society of Hypertension. Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. J Hypertens 2009;27(11):2121-58
13. Calhoun DA, Lacourciere Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: A randomized clinical trial. Hypertension 2009;54(1):32-9
14. Deeks ED. Amlodipine/valsartan/ hydrochlorothiazide: Fixed-dose combination in hypertension. Am J Cardiovasc Drugs 2009;9(6):411-18
15. Oparil S, Melino M, Lee J, et al. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther 2010; 32(7):1252-69
16. Destro M, Crikelair N, Yen J, Glazer R. Triple combination therapy with amlodipine, valsartan and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients. Vasc Health Risk Manag 2010; 6:821-17
17. Wright RF, Duprez D, Purkayastha D, et al. Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: The exforge as compared to losartan treatment in stage 2 systolic hypertension (EXALT) study. J Clin Hypertens (Greenwich) 2011;13(8):588-97
18. Laffer CL, Elijovich F. A critical appraisal of the clinical effectiveness of a fixed combination of valsartan, amlodipine, and hydrochlorothiazide in achieving blood pressure goals. Integr Blood Press Control 2011;4:1-5
19. Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54(2):299-311 (Pubitemid 27361837)
20. Scott LJ, McCormack PL. Olmesartan medoxomil: A review of its use in the management of hypertension. Drugs 2008;68(9):1239-72 (Pubitemid 351822113)
21. Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective randomized open blinded end-point. Blood Press 1992;1(2):113-19
22. Parati G, Bosi S, Castellano M, et al. Guidelines for 24-hour non invasive ambulatory blood pressure monitoring: Report from a working group of the Italian Society of hypertension. High Blood Press 1995;4:168-74
23. Novartis Pharmaceutical Corp. Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) tablets: US prescribing information (online). Available from: . fda.gov/drugsatfda-docs/label/2009/ 022314lbl.pdf
24. Fogari R, Zoppi A, Mugellini A, et al. Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. Adv Ther 2006;23(5):680-95 (Pubitemid 44955847)
25. Bhad P, Ayalasomayajula S, Karan R, et al. Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension. J Clin Pharmacol 2011;51(6):933-42
26. Cook NR, Cohen J, Hebert PR, et al. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995;155(7):701-9
27. Julius S, Kjeldsen SE, Weber M, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004;363(9426):2022-31 (Pubitemid 38781102)